Journal article
Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib
Authors
Garcia-Horton A; Smith E; Maze D; McNamara C; Sibai H; Gupta V
Journal
Leukemia & Lymphoma, Vol. 62, No. 2, pp. 495–497
Publisher
Taylor & Francis
Publication Date
January 28, 2021
DOI
10.1080/10428194.2020.1832671
ISSN
1042-8194